Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).Asim Amin, Hans J. Hammers, Brian I. Rini et al.|Journal of Clinical Oncology|2014Cited by 233
Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).Hans J. Hammers, Asim Amin, Elizabeth R. Plimack et al.|Journal of Clinical Oncology|2015Cited by 66